Related Experiment Video

Updated: May 25, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing

Claudia Saracini1, Anna Vestrini, Silvia Galora

  • 1Department of Medical and Surgical Critical Care, University of Florence-Atherothrombotic Diseases Center, AOU Careggi, Florence, Italy. claudiasaracini@hotmail.it

Genetic Testing and Molecular Biomarkers
|January 14, 2012
PubMed

Insights

The Verigene system accurately identifies clopidogrel poor metabolizer status, offering faster results and lower overall costs compared to TaqMan. This genetic testing aids in selecting optimal antiplatelet therapy for cardiovascular patients.

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Clinical Chemistry

Background:

  • CYP2C19 variant alleles influence clopidogrel response and cardiovascular event risk.
  • Platelet function and CYP2C19 genetic testing can identify high-risk patients needing alternative antiplatelet strategies.
  • Test accuracy, cost, and result availability are critical for clinical implementation of genetic testing.

Purpose of the Study:

  • To compare the Verigene and TaqMan platforms for CYP2C19 genotyping in acute coronary syndrome patients.
  • To evaluate the turnaround time and cost-effectiveness of the Verigene system versus TaqMan.
  • To assess the clinical utility of rapid CYP2C19 genotyping for antiplatelet therapy decisions.

Main Methods:

  • Genotyping of CYP2C19*2,*3,*4,*5, and *17 polymorphisms in 100 acute coronary syndrome patients.
  • Comparison of results obtained from the Verigene system and the TaqMan system.
  • Analysis of turnaround time and cost, including reagent and staff involvement.

Main Results:

  • 100% concordance in genotyping results between Verigene and TaqMan for all five polymorphisms.
  • Verigene system demonstrated a significantly shorter turnaround time compared to TaqMan.
  • Despite lower reagent costs for TaqMan, Verigene offered a lower overall cost due to reduced manual staff involvement.

Conclusions:

  • The Verigene system shows excellent performance for evaluating clopidogrel poor metabolizer status.
  • Verigene provides genetic information within a clinically relevant timeframe (206 minutes) for therapeutic decisions.
  • The Verigene system is a cost-effective and rapid method for CYP2C19 genotyping in clinical practice.
Abstract

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...